AOD-9604: The HGH Fragment Studied for Fat Loss

AOD-9604 is a modified fragment of human growth hormone (HGH) that was developed in the 1990s and 2000s as an anti-obesity drug. It reduced body fat in obese mice, but human trials did not show enough weight loss to continue development, and AOD-9604 has never been FDA approved.

It still appears in clinic advertising and online stores, so it deserves a clear, evidence-aware look.

What Is AOD-9604?

Growth hormone is a 191-amino-acid protein with many effects: it promotes growth, raises IGF-1, affects blood sugar, and helps release stored fat. Researchers noticed that the fat-releasing (lipolytic) activity seemed to sit near the end of the molecule, around amino acids 176–191.

AOD-9604 ("Anti-Obesity Drug 9604") is that 176–191 fragment with an extra tyrosine added. The idea was elegant: keep growth hormone's fat-burning signal while leaving behind its effects on growth, IGF-1 and blood sugar.

How AOD-9604 Is Thought to Work

According to laboratory and animal research:

• Lipolysis: It appears to stimulate the breakdown of stored triglycerides in fat cells.
• Reduced fat storage: Animal data suggest it may inhibit new fat formation (lipogenesis).
• No classic GH-receptor effect: It does not appear to activate the growth hormone receptor the way full-length HGH does, which is why it was not expected to raise IGF-1 or blood sugar.

A 2001 study in Endocrinology found that both growth hormone and AOD-9604 reduced body weight and fat in obese mice. Researchers also reported a possible chondroprotective (cartilage-supporting) effect in later animal models of osteoarthritis, but that evidence is limited to animal studies.

What Human Trials Showed

AOD-9604 went further than many peptides: it was tested in a series of randomized, placebo-controlled human trials sponsored by its developer.

• Safety: A published summary of six randomized, double-blind trials reported that AOD-9604 had a safety and tolerability profile described as indistinguishable from placebo. It did not change IGF-1 levels, did not worsen glucose tolerance, and did not provoke detectable antibodies.
• Efficacy: A larger phase 2b obesity trial did not show weight loss meaningfully better than placebo, and the obesity drug program was discontinued.

That is an important lesson. A compound can be well tolerated and still not work well enough to matter. When I hear AOD-9604 described as a "proven fat burner," I point out that the most rigorous human data say otherwise.

Why would a peptide that worked in mice disappoint in people? This happens often in obesity research. Rodent metabolism runs much faster than ours, laboratory obesity models do not capture the complexity of human appetite and behavior, and the body tends to defend its weight through compensating hunger and energy-saving signals. A modest increase in fat breakdown can simply be offset elsewhere. That gap between animal promise and human results is exactly why I put far more weight on controlled human trials than on mechanism alone.

Regulatory Status

• AOD-9604 is not FDA approved for any use.
• In 2023, FDA placed it in "Category 2" of the 503A bulk-substance list, which signals safety concerns for compounding.
• In December 2024, FDA's Pharmacy Compounding Advisory Committee voted against adding AOD-9604 to the list of substances pharmacies may compound. It was not among the peptides FDA moved for re-review in April 2026.

Why People Still Ask About It

Most patients who ask about AOD-9604 are frustrated with stubborn abdominal fat despite real effort. That frustration is valid, and it deserves a real workup rather than an unproven injection. In my experience, the useful questions are:

• Is insulin resistance present? Fasting insulin, glucose and HbA1c often reveal it before diabetes develops. See metabolic health markers every adult should track.
• Are hormones contributing? Thyroid function, testosterone in men, perimenopausal changes in women, and cortisol patterns can all shift body composition.
• Are sleep and stress sabotaging progress? Short sleep and untreated sleep apnea strongly affect appetite and fat storage.
• Is muscle being preserved? Resistance training and adequate protein protect lean mass during fat loss.

Evidence-Based Alternatives

If a medication is appropriate, there are options with far stronger evidence:

• GLP-1 and dual GIP/GLP-1 medicines such as semaglutide and tirzepatide are FDA approved for chronic weight management in eligible patients and have large randomized trials behind them. I discuss their role in GLP-1 medications and longevity.
• Tesamorelin is FDA approved for reducing excess abdominal fat in people with HIV-associated lipodystrophy. Its use outside that indication is off-label and needs individual judgment.

Each of these has known side effects and requires monitoring, which is exactly why they belong inside a medical relationship.

How I Approach Fat-Loss Questions

At Laeeq M.D., I start with a metabolic evaluation: body composition, waist circumference, fasting labs, thyroid and hormone testing where indicated, a medication review and a sleep history. Then we build a plan around nutrition, training and, when appropriate, FDA-approved medication. I will tell you plainly when a popular compound, like AOD-9604, does not have the evidence to justify it. You can see the full AOD-9604 evidence summary in our peptide library.

Sources

• The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice — Endocrinology, 2001. https://pubmed.ncbi.nlm.nih.gov/11713213/
• Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans — Journal of Endocrinology and Metabolism, 2013. https://jofem.org/index.php/jofem/article/view/157

Book a Consultation

If stubborn weight has not responded to your efforts, a thorough metabolic evaluation is a better first step than an unproven peptide. You can book a consultation for a 60-minute visit with Dr. Laeeq, virtually or in person in Reston, VA.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.